Bender Jeremy 4

Accession 0001863107-25-000005

CIK 0001845337other

View on SEC.gov Company Profile

Filed

Nov 17, 7:00 PM ET

Accepted

Nov 18, 6:59 PM ET

Size

25.0 KB

Accession

0001863107-25-000005

Insider Transaction Report

Form 4

Period: 2025-11-15

Day One Biopharmaceuticals, Inc.DAWN

Bender Jeremy

DirectorCHIEF EXECUTIVE OFFICER

Transactions

Exercise/Conversion
Common Stock
2025-11-15+11,687→ 181,372 total
Exercise/Conversion
Common Stock
2025-11-15+11,687→ 193,059 total
Sale
Common Stock
2025-11-17$8.91/sh−15,894$141,690→ 177,165 total
Exercise/Conversion
Restricted Stock Unit (RSU)
2025-11-15−3,570→ 0 total
→ Common Stock (3,570 underlying)
Exercise/Conversion
Common Stock
2025-11-15+3,570→ 164,935 total
Exercise/Conversion
Restricted Stock Unit (RSU)
2025-11-15−11,687→ 140,252 total
→ Common Stock (11,687 underlying)
Exercise/Conversion
Common Stock
2025-11-15+4,750→ 169,685 total
Exercise/Conversion
Restricted Stock Unit (RSU)
2025-11-15−4,750→ 19,000 total
→ Common Stock (4,750 underlying)
Exercise/Conversion
Restricted Stock Unit (RSU)
2025-11-15−11,687→ 93,504 total
→ Common Stock (11,687 underlying)

Holdings

Common Stock
(indirect: See footnote)
20,204
Common Stock
(indirect: See footnote)
147,702
Common Stock
(indirect: See footnote)
18,197
Common Stock
(indirect: See footnote)
14,450
Common Stock
(indirect: See footnote)
1,408,285

Footnotes (10)

[F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
[F10]RSUs do not expire; they either vest or are canceled prior to the vesting date.
[F2]The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $8.545 to $9.305, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade.
[F4]Represents shares held by The Jeremy Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person is trustee.
[F5]Represents shares held by The Jeremy Bender 2023 Grantor Retained Annuity Trust dated June 27, 2023.
[F6]Represents shares held by The Melissa Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person's spouse is trustee.
[F7]Represents shares held by The Melissa Bender 2023 Grantor Retained Annuity Trust, dated June 27, 2023.
[F8]Represents shares held by the Bender Revocable Trust dated January 18, 2017, as amended, Jeremy Bender and Melissa C. Bender, Trustees.
[F9]The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Documents

1 file

4
form4-11182025_111119.xmlPrimary

Issuer

Day One Biopharmaceuticals, Inc.

CIK 0001845337

→

Entity typeother

Related Parties

filerCIK 0001863107

Filing Metadata

Form type: 4
Filed: Nov 17, 7:00 PM ET
Accepted: Nov 18, 6:59 PM ET
Size: 25.0 KB

View on SEC.gov